Kymera Therapeutics, Inc.
KYMR
Rang in aandelen
#2168
Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to... Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and developing pioneering small molecule therapeutics. These treatments operate by harnessing the body's inherent protein degradation system to selectively eliminate disease-causing proteins. The company's pipeline features several programs, including the IRAK4 program, currently in Phase I clinical trials, which targets various immunology-inflammation disorders such as hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, generalized pustular psoriasis, and rheumatoid arthritis. Additionally, Kymera is advancing its IRAKIMiD program, designed to address MYD88-mutated diffuse large B cell lymphoma. Other key programs include the STAT3 program, focused on hematological malignancies, solid tumors, autoimmune diseases, and fibrosis, as well as the MDM2 program, which is also aimed at hematological malignancies and solid tumors. The company was founded in 2015 and maintains its headquarters in Watertown, Massachusetts.
Aandeelprijs
$114.80
Marktkapitalisatie
$9.44B
Verandering (1 dag)
1.18%
Verandering (1 jaar)
96.84%
Land
US
Handel Kymera Therapeutics, Inc. (KYMR)
Categorie
Healthcare
Omzet van Kymera Therapeutics, Inc. (KYMR)
Omzet in Jun 2026 TTM: $104.99M
Volgens de laatste financiële rapporten van Kymera Therapeutics, Inc. bedraagt de huidige omzet van het bedrijf (TTM) $104.99M. In 2023 behaalde het bedrijf een omzet van $78.59M een stijging ten opzichte van de omzet in het jaar 2022, die $46.83M bedroeg. De omzet is het totale bedrag aan inkomsten dat een bedrijf genereert door de verkoop van goederen of diensten. In tegenstelling tot de winst worden er geen kosten afgetrokken.
Omzetgeschiedenis van Kymera Therapeutics, Inc. van 2018 tot 2026
Omzet aan het einde van elk jaar
| Jaar | Omzet | Wijzigen |
|---|---|---|
| 2026 (TTM) | $104.99M | 123.04% |
| 2024 | $47.07M | -40.11% |
| 2023 | $78.59M | 67.84% |
| 2022 | $46.83M | -35.71% |
| 2021 | $72.83M | 114.00% |
| 2020 | $34.03M | 1,059.99% |
| 2019 | $2.93M | 0.00% |
| 2018 | 0.00 | 0.00% |
Omzet van vergelijkbare bedrijven of concurrenten
| Bedrijf | Omzet | Omzetverschil | Land |
|---|---|---|---|
| $12.62B | 11,924.40% |
US
|
|
| $2.23B | 2,022.13% |
US
|
|
| $15.74B | 14,896.17% |
AU
|
|
| $6.02B | 5,635.16% |
NL
|
|
| - | - |
CH
|
